Drug Type Synthetic peptide |
Synonyms SP 16, SP-16, SP16 |
Target |
Action agonists |
Mechanism LRP1 agonists(LDL receptor related protein 1 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC34H48N2O3 |
InChIKeyUTKQYACBDGXDMC-UHFFFAOYSA-N |
CAS Registry60168-17-4 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Acute Lung Injury | Phase 2 | - | - | |
| COVID-19 | Phase 1 | United States | 01 Dec 2021 | |
| Inflammation | Phase 1 | United States | 16 Jul 2018 | |
| Eosinophilic Esophagitis | Preclinical | United States | 02 Nov 2023 | |
| Diabetes Mellitus | Preclinical | United States | 26 Sep 2013 | |
| Acute Kidney Injury | Preclinical | United States | - | |
| Alopecia Areata | Preclinical | United States | - | |
| Dermatitis, Atopic | Preclinical | United States | - | |
| Neuralgia | Preclinical | United States | - |
Phase 1/2 | 10 | vrekkestto(otinoncbtk) = wldwspspby tnymyspibw (tlavcdtpxw, bnklrwrwpx - bqotxpiang) View more | - | 30 Jan 2023 | |||
Phase 1/2 | 10 | qjxjzovpsl(hfgmykrvps) = All ten patients with STEMI received subcutaneous administration of SP16, 381 [272 to 478] minutes after PCI, without any treatment-related adverse events bwwxxkcash (aejrxpddtn ) | Positive | 12 Jul 2022 | |||
Placebo | |||||||
NCT03651089 (Pubmed) Manual | Phase 1 | - | 24 | hubesyvwct(zanvxcmgif) = nyuidkwctu ckrqxommhk (fucinnfdap ) View more | Positive | 06 May 2021 | |
Placebo | hubesyvwct(zanvxcmgif) = gmnrvdsupf ckrqxommhk (fucinnfdap ) View more |






